Compared with KRAS-wild-type (WT) tumors, TMB-high status was less frequent in KRAS-mutated tumors both in the overall cohort (9.48% v 10.51%, OR = 0.89, and FDR-P = .004) and in the CRC cohort (4.68 v 10.34%, OR = 0.43, and FDR-P < .0001). This evidence concerns the gene KRAS and colorectal carcinoma.